Tag Archives: TAVR

The Written (Worlwide TAVI Experience) Survey

The Written (Worlwide TAVI Experience) Survey

Letter from Dr. José Armando Mangione, President of SOLACI. Dear Colleagues, We kindly request you to take part in our survey about cotemporary TAVI practices in Latin American (LATAM) centers. It has been developed for the WRITTEN study, which assessed TAVI practices in 250 centers around the world (29 in LATAM) between March and September 2015.

El reemplazo transcatéter en válvulas bicúspides suma evidencia pero continúan los desafíos

TAVR in Bicuspid Has the Same Results in Surgery at Hospital Level

Courtesy of Dr. Carlos Fava. Bicuspid aortic stenosis patients (bicuspid AS) represent a small group and have not been included in the larger transcatheter aortic valve replacement (TAVR) studies, since they present different morphology and asymmetric calcification, which might come along with more paravalvular leak and less accurate positioning. Between 2012 and 2016, 475,315 patients

Protrusión de placa en angioplastia carotidea ¿Qué riesgo implica y cómo prevenirlo?

The Real Impact of Peripheral Artery Disease in TAVR

Courtesy of Dr. Carlos Fava. The real incidence of peripheral artery (PAD) disease in TAVR remains unclear. Different reports still estimate it is between 10 and 46%, but they have shown it has a negative impact in evolution. 51,685 TAVR patients were analyzed. 12,740 of these patients presented PAD (24.6%). PAD patients tended to be

¿Fin de la discusión sobre el impacto del marcapaso post TAVI?

Experts Reach Consensus on Post TAVR Pacemaker Indication

This new consensus published this week in J Am Coll Cardiol has provided us with an algorithm to manage conduction disturbances after transcatheter aortic valve replacement. This consensus is intended to reduce potential deaths caused by conduction disturbances and, at the same time, reduce unnecessary definite pacemaker implantation. This document is a big step ahead

La prudencia es buena consejera para decidir una transfusión en el TAVI

FDA Expands TAVR Indication to Low-Risk Patients

Both the self-expandable valve Evolut R and its direct competitor, balloon-expandable valve Sapien 3, received the authorization to be indicated for low-risk patients in a long-awaited announcement made on August 16th, 2019. The US Food and Drug Administration (FDA) has approved and expanded the indication for the Evolut series (Medtronic) and the Sapien 3 and

El alta en el mismo día luego de una angioplastia coronaria es cada vez más popular pero todavía no es regla

Next-Day Discharge after TAVR: Equally Safe for All Prosthesis?

Yet scarce, there is evidence supporting next-day discharge (NDD) after TAVR is safe when patients receiving balloon expandable valves meet certain conditions. This had not yet been shown for self-expandable valves. This study looks into NDD after TAVR by femoral access with self-expandable valves.  The authors retrospectively compared all consecutive patients undergoing elective minimalist TAVR

Endocarditis y TAVI, una complicación rara pero devastadora

Prosthetic Valve Endocarditis and TAVR: though Rare, Devastating

On the bright side, the incidence of prosthetic valve endocarditis (PVE) post TAVR is not higher than post SAVR, according to this study recently presented at EuroPCR 2019, held in Paris. There is plenty of evidence describing PVE incidence, prognosis, risk factors, etc. after surgical valve replacement surgery (SAVR). However, we know little about the

Impacto negativo de la hipertensión pulmonar en el TAVI

Pulmonary Hypertension: No Reason for TAVR Contraindication

In most severe aortic stenosis patients with pulmonary hypertension, transcatheter aortic valve replacement (TAVR) reduced pulmonary systolic pressure. There patients presented lower risk and lower all-cause mortality at short, median and long term. This data show that pulmonary hypertension should not be a TAVR contraindication. Pulmonary hypertension is common among TAVR patients. The most frequent

Incidence, Characteristics, and Treatment of Valve Thrombosis After TAVR

Low-Risk TAVR Trending in All Papers

Transcatheter aortic valve replacement (TAVR) in low-risk patients with symptomatic severe aortic stenosis appears to be safe at one year. In a follow-up using computerized tomography (TC), hypoattenuated leaflet thickening was observed in a minority of patients, but it did not have a long-term hemodynamic impact. It should be noted that the management strategy for

Estenosis aórtica severa asintomática en añosos: ¿cuándo intervenir?

Safe for 80-Year-Olds. Should Nonagenarians be Withheld from TAVR?

According to this large global registry, mortality after transcatheter aortic valve replacement (TAVR) is twice as high in nonagenarians as against the “younger” group (90 patients. Additionally, risk scores cannot be trusted given that on the one hand they were designed for patients with planned surgery, and on the other hand, they included few patients

Top